Kevin MD - Jasper Therapeutics Ex RD
| JSPR Stock | USD 22.81 0.43 1.85% |
Insider
Kevin MD is Ex RD of Jasper Therapeutics
| Age | 53 |
| Address | 2200 Bridge Pkwy, Redwood City, CA, United States, 94065 |
| Phone | 650 549 1400 |
| Web | https://www.jaspertherapeutics.com/ |
Jasper Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.4092) % which means that it has lost $0.4092 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7146) %, meaning that it created substantial loss on money invested by shareholders. Jasper Therapeutics' management efficiency ratios could be used to measure how well Jasper Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 12/01/2024, Return On Tangible Assets is likely to drop to -0.71. In addition to that, Return On Capital Employed is likely to drop to -0.88. At this time, Jasper Therapeutics' Net Tangible Assets are relatively stable compared to the past year. As of 12/01/2024, Other Current Assets is likely to grow to about 1.9 M, while Total Assets are likely to drop slightly above 63.2 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| MSc MBA | Inozyme Pharma | 52 | |
| Lori Friedman | Oric Pharmaceuticals | 60 | |
| Joern Aldag | Hookipa Pharma | 65 | |
| Quinn Deveraux | Inhibrx | N/A | |
| Daniel Iazzetti | Oric Pharmaceuticals | N/A | |
| Gregory Flesher | Eledon Pharmaceuticals | 54 | |
| Uli Bialucha | Xilio Development | N/A | |
| BCPS PharmD | Xilio Development | 47 | |
| Scott Lowe | Oric Pharmaceuticals | N/A | |
| Susan MS | Eliem Therapeutics | N/A | |
| Alfredo Castro | Ikena Oncology | N/A | |
| James JD | Eliem Therapeutics | 58 | |
| Julie CPA | Design Therapeutics | N/A | |
| BS CPA | Inhibrx | 42 | |
| Martin MD | Xilio Development | 63 | |
| Aseem Ansari | Design Therapeutics | N/A | |
| Jeffrey Ecsedy | Ikena Oncology | 54 | |
| Russell MS | Acumen Pharmaceuticals | 66 | |
| MA MS | Inozyme Pharma | N/A | |
| CMA CPA | ESSA Pharma | 65 | |
| MBA MBA | Inozyme Pharma | 65 | |
Management Performance
| Return On Equity | -0.71 | ||||
| Return On Asset | -0.41 |
Jasper Therapeutics Leadership Team
Elected by the shareholders, the Jasper Therapeutics' board of directors comprises two types of representatives: Jasper Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Jasper. The board's role is to monitor Jasper Therapeutics' management team and ensure that shareholders' interests are well served. Jasper Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Jasper Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ronald Martell, CEO President | ||
| Herbert Cross, CFO Secretary | ||
| Luca Noto, Senior Operations | ||
| Carol Zoltowski, VP Quality | ||
| Herbert CPA, CFO Secretary | ||
| Jeetinder MBA, Chief Officer | ||
| Wendy MD, Senior Medicine | ||
| Patricia Carlos, Senior Quality | ||
| Matthew Ford, Vice Resources | ||
| Edwin MD, Chief Officer | ||
| Judith MD, CoFounder Director | ||
| Susan Prohaska, CoFounder Management | ||
| Kevin MD, Ex RD | ||
| David MD, Portfolio Development |
Jasper Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Jasper Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.71 | ||||
| Return On Asset | -0.41 | ||||
| Current Valuation | 251.75 M | ||||
| Shares Outstanding | 15 M | ||||
| Shares Owned By Insiders | 4.98 % | ||||
| Shares Owned By Institutions | 95.02 % | ||||
| Number Of Shares Shorted | 1.94 M | ||||
| Price To Book | 4.09 X | ||||
| EBITDA | (64.98 M) | ||||
| Net Income | (64.47 M) |
Pair Trading with Jasper Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Jasper Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Jasper Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Jasper Stock
| 0.56 | HCM | HUTCHMED DRC | PairCorr |
| 0.47 | ZTS | Zoetis Inc | PairCorr |
| 0.4 | LLY | Eli Lilly | PairCorr |
| 0.39 | RDY | Dr Reddys Laboratories | PairCorr |
| 0.37 | PFE | Pfizer Inc Aggressive Push | PairCorr |
The ability to find closely correlated positions to Jasper Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Jasper Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Jasper Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Jasper Therapeutics to buy it.
The correlation of Jasper Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Jasper Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Jasper Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Jasper Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Jasper Stock Analysis
When running Jasper Therapeutics' price analysis, check to measure Jasper Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jasper Therapeutics is operating at the current time. Most of Jasper Therapeutics' value examination focuses on studying past and present price action to predict the probability of Jasper Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jasper Therapeutics' price. Additionally, you may evaluate how the addition of Jasper Therapeutics to your portfolios can decrease your overall portfolio volatility.